Skip to main content

CCTG Connection



Published:
Category: Group updates
CCTG Recognition Awards - Call for Nominations
The Canadian Cancer Trials Group is seeking nominations for the 2024 Recognition Awards honouring individuals who have contributed significantly to the mission and activities of the Group. Read More

Published:
Category: Group updates
EDIIA Virtual Round Table: March 5
Please join CCTG on March 5 from 1:30 to 3:00 pm EST for a virtual roundtable on integrating equity, diversity, and inclusion in cancer clinical trials. We look forward to welcoming Dr. Doreen Ezeife, Dr. Carmen Guerra, and Dr. Tina Hsu to lead us in this conversation which will be moderated by CCTG Senior Investigator Dr. Wendy Parulekar. Read More

Published:
Category: Group updates
CCTG Annual Spring Meeting of Participants May 3 - 5 - meeting in progress

The CCTG Annual Spring Meeting of Participants will be held Friday, May 3 to Sunday, May 5 at the Chelsea Hotel in Toronto. Here are some updates if you are planning on joining us.

Meeting Invitations

If you are planning meetings and/or attending the Spring Meeting be sure to read your Invitation carefully so you are clear on the funding support associated with your Invitation.

Read More

Published:
Category: Office of the Director
By Janet Dancey Contributor - Clinical trials are the most effective means of ensuring we have better cancer treatments. 

Clinical trials are the most effective means of ensuring we have better cancer treatments. Such an investment would help overcome many hurdles facing clinical trials – from underfunding and suboptimal testing capacity to inefficient and costly regulatory processes.

By Janet Dancey Contributor

From the Toronto Star Opinion Page - Monday, February 19, 2024

Read More

Published:
Category: Publications
Publications: SRC6 substudies
Two SRC6 sub studies: Outcomes After Preoperative Chemoradiation With or Without Pazopanib in Non-Rhabdomyosarcoma Soft Tissue Sarcoma and Neoadjuvant pazopanib in nonrhabdomyosarcoma soft tissue sarcomas Read More

Published:
Category: Publications
Publication: MA36

Patient-Reported Outcomes in OlympiA: A Phase III, Randomized, Placebo-Controlled Trial of Adjuvant Olaparib in gBRCA1/2 Mutations and High-Risk Human Epidermal Growth Factor Receptor 2–Negative Early Breast Cancer. 

Read More

Published:
Category: Trials
Closed to Accrual CCTG CRC.9 trial (NRG-GI005) (NCT04068103)
The CCTG CRC.9 trial (NRG-GI005) (NCT04068103) Phase II/III Study of Circulating tumour DNA as a Predictive BiomarRker in Adjuvant Chemotherapy in Patients with Stage IIA Colon Cancer has closed to accrual. After a recent interim analysis it was determined that the trial should halt recruitment. 
 
This phase II/III trial studied how well circulating tumor deoxyribonucleic acid (ctDNA) testing in the blood works in predicting treatment for patients with stage IIA colon cancer after surgery.
Read More

Published:
Category: Trials
Permanent Trial Closure: ALC2
Please be aware of the permanent trial closure of the ALC2 (CALGB C10603) A Phase III Randomized, Double-Blind Study of Induction (Daunorubicin/Cytarabine) and Consolidation (High-Dose Cytarabine) Chemotherapy + Midostaurin (PK412) (IND # 101261) or Placebo in Newly Diagnosed Patients < 60 Years of Age With FLT3 Mutated Acute Myeloid Leukemia (AML) trial.
Read More